In addition, a syngeneic murine model of EGFR-mutant lung tumor recently highlighted the immunosuppressive effects of tumor-associated macrophages on T cells CD8+, thus impairing the efficacy of osimertinib (a third-generation EGFR-TKI)39. This evidence concerns the gene CD8A and neoplasm.